Niclosamide With Etanercept in Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2018-12-10
• Target enrollment: 0
• Participant gender: All

Summary

Assessment of the adjuvant use Niclosamide With Etanercept in Rheumatoid Arthritis

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Faiq Gorial
• Treatments: Etanercept; Niclosamide

Criteria

Inclusion Criteria:

• Patients with RA, as defined by the American College of Rheumatology (ACR) 1987 revised criteria or ACR/EULAR 2010,

• Severly Active RA by calculating either DAS28 or SDAI or CDAI.

• Patient selected are those who started etanercept for less than 3months and still active.

Exclusion Criteria:

• Patients on nonsteroidal anti-inflammatory drugs (NSAID) 2 days before entry into this study. or methotrexate (MTX)..

• Patients with hypersensitivity or severe adverse effects to niclosamide .

• Renal impairment.

• Hepatic impairment.

• Pregnancy or a desire to become pregnant.

• Breast feeding.

• Patients with Juvenile RA [16 years old or younger].

• Patients using other conventional disease modifying antirheumatic drugs (DMARDs).

• Patients on steroid.

• Patients with coexistence other connective tissue diseases or hypothyroid disease.

• Patient with mild or inactive RA.